- Home
- EDBL vs WINT Comparison
EDBL vs WINT Comparison
Compare EDBL & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDBL
- WINT
- Stock Information
- Founded
- EDBL 2020
- WINT 1992
- Country
- EDBL United States
- WINT United States
- Employees
- EDBL N/A
- WINT N/A
- Industry
- EDBL Farming/Seeds/Milling
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDBL Consumer Staples
- WINT Health Care
- Exchange
- EDBL Nasdaq
- WINT Nasdaq
- Market Cap
- EDBL 3.3M
- WINT 3.6M
- IPO Year
- EDBL 2022
- WINT 1995
- Fundamental
- Price
- EDBL $1.97
- WINT $0.83
- Analyst Decision
- EDBL
- WINT Hold
- Analyst Count
- EDBL 0
- WINT 1
- Target Price
- EDBL N/A
- WINT $350.00
- AVG Volume (30 Days)
- EDBL 64.7K
- WINT 224.2K
- Earning Date
- EDBL 05-15-2025
- WINT 05-16-2025
- Dividend Yield
- EDBL N/A
- WINT N/A
- EPS Growth
- EDBL N/A
- WINT N/A
- EPS
- EDBL N/A
- WINT N/A
- Revenue
- EDBL $13,443,000.00
- WINT N/A
- Revenue This Year
- EDBL $29.56
- WINT N/A
- Revenue Next Year
- EDBL $20.00
- WINT N/A
- P/E Ratio
- EDBL N/A
- WINT N/A
- Revenue Growth
- EDBL N/A
- WINT N/A
- 52 Week Low
- EDBL $1.82
- WINT $1.01
- 52 Week High
- EDBL $230.00
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- EDBL 41.06
- WINT 29.36
- Support Level
- EDBL $1.89
- WINT $0.81
- Resistance Level
- EDBL $2.40
- WINT $0.95
- Average True Range (ATR)
- EDBL 0.18
- WINT 0.09
- MACD
- EDBL 0.04
- WINT 0.04
- Stochastic Oscillator
- EDBL 21.48
- WINT 6.14
About EDBL Edible Garden AG Incorporated
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.